The site ww.cialweb.com presents a new article dedicated to the issue of prescribing phosphodiesterase type 5 inhibitors against erectile dysfunction (ED) for patients with cardiovascular diseases. In this large study, the papers of Shabber Abbas, BS, and Jacqueline Lanoix, PhD were used. Dr. Nehra, a consultant for the pharmaceutical concern Pfizer, left his notes about this study.
The article contains detailed consideration of the intake of PDE-5 inhibitors against ED in patients with hypertension, dyslipidemia, diabetes and cardiovascular diseases. This information will be of interest to both ordinary patients and those with medical background, including practicing urologists.
The complete text of the article is available HERE